Circulating miR-146a-5p and miR-132–3p as potential diagnostic biomarkers in epilepsy

Abstract

ObjectiveMiRNAs are important gene-regulating agents in epilepsy development, according to new research. The purpose of this study is to investigate the relationship between serum expression of miR-146a-5p and miR-132–3p and epilepsy in Egyptian patients as potential diagnostic and therapeutic biomarkers. MethodsMiR-146a-5p and miR-132–3p were measured in the serum of 40 adult epilepsy patients and 40 controls using real-time polymerase chain reaction. The comparative cycle threshold (CT) approach (2–ΔΔCT) was used to compute relative expression levels, which were normalized to cel-miR-39 expression and compared to healthy controls. The diagnostic performance of miR-146a-5p and miR-132–3p was assessed using receiver operating characteristic curve analysis. ResultsThe relative expression levels of miR-146a-5p and miR-132–3p in serum were considerably greater in epilepsy patients than in the control group. There was a significant difference in the miRNA-146a-5p relative expression in the focal group when the non-responders were compared with the responders’ groups, and a significant difference when comparing the non-responders’ focal and the non-responders’ generalized groups, however, univariate logistic regression analysis revealed that increased seizure frequency is the only risk factor among all factors affecting the drug response There was a significant difference in epilepsy duration between miR-132–3p high and low expression. With an area under the curve of 0.714 (95% C. I 0.598–0.830; P = 0.001), the combined miR-146a-5p and miR-132–3p serum levels performed better than each separately as a diagnostic biomarker to distinguish epilepsy patients from controls. SignificanceThe findings imply that both miR-146a-5p and miR-132–3p may be involved in epileptogenesis regardless of epilepsy subtypes. Although the combined circulating miRNAs may be useful as a diagnostic biomarker, they are not a predictor of drug response. MiR-132–3p might be used to predict epilepsy's prognosis by demonstrating its chronicity.